Literature DB >> 6702820

Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome.

F J Frey, B M Frey.   

Abstract

Prednisolone binds in plasma to both albumin and transcortin. Since altered concentrations of plasma proteins change capacity and association constants of the drug-protein complex and thus influence the disposition of the drug, the kinetics of prednisolone following oral prednisone and intravenous (IV) prednisolone were studied in ten nephrotic patients and in 12 healthy volunteers. Compared to normal volunteers, nephrotic patients had significantly higher mean (+/- SD) association constants for the albumin-prednisolone complex (4.20 +/- 2.10 X 10(3) M-1 v 2.26 +/- 0.46 X 10(3) M-1, P less than 0.005) and tended to have higher association constants for the transcortin-prednisolone complex. Following the IV administration of prednisolone and the oral administration of prednisone, nephrotic patients exhibited lower total plasma concentrations of prednisolone than did normal volunteers. The difference was attributable to lower albumin-bound and/or transcortin-bound, but not unbound, concentrations of prednisolone in plasma. The mean prednisolone bioavailability from oral prednisone was not different between nephrotic patients and controls. When calculated with reference to total prednisolone concentrations in plasma, the mean nonrenal clearance rate, but not the mean renal clearance rate, was higher in the nephrotic patients than in the controls (2.63 +/- 0.61 mL/min/kg v 1.85 +/- 0.33 mL/min/kg, P less than 0.005). Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005). Nephrotic patients had lower ratios of unbound prednisolone clearance/creatinine clearance (fractional excretion) after IV prednisolone (1.50 +/- 0.81 v 2.27 +/- 0.49, P less than 0.025) or after oral prednisone (1.07 +/- 0.60 v 2.12 +/- 0.77, P less than 0.005) than the controls. Since these fractional excretion values of unbound prednisolone exceeded one, there must be glomerular filtration of prednisolone bound to plasma proteins and/or tubular secretion of prednisolone. This study indicates that the nephrotic dysproteinemia changes the binding of prednisolone to plasma proteins not only in point of quantity, but also in point of quality, and alters the disposition of prednisolone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6702820     DOI: 10.1016/s0272-6386(84)80081-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers.

Authors:  Stefan Farese; Emilie Stauffer; Robert Kalicki; Tatjana Hildebrandt; Brigitte M Frey; Felix J Frey; Dominik E Uehlinger; Andreas Pasch
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

4.  The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone.

Authors:  F J Frey; M K Rüegsegger; B M Frey
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

5.  Prednisolone protein binding in renal transplant patients.

Authors:  P A Reece; A P Disney; I Stafford; J C Shastry
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

6.  Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone.

Authors:  B M Frey; H J Schaad; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  [Transcortin concentrations in the plasma of normal persons and patients with kidney and liver diseases].

Authors:  B M Frey; T Hugentobler; M Bührer; F J Frey
Journal:  Klin Wochenschr       Date:  1984-10-01

Review 8.  Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome.

Authors:  Anne M Schijvens; Rob Ter Heine; Saskia N de Wildt; Michiel F Schreuder
Journal:  Pediatr Nephrol       Date:  2018-03-16       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.